Daxor Corporation
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $61.4M
- Price
- $10.51
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.04%
- Volume
- 7.4K
About
Based in Oak Ridge, Tennessee, Daxor Corporation is a medical technology enterprise founded in 1971. The company specializes in blood volume measurement, developing and commercializing the BVA-100 Blood Volume Analyzer. This diagnostic instrument offers a precise, objective method for quantifying a patient's blood volume status and composition, comparing these metrics against their unique physiological norms. It is utilized across a wide spectrum of medical and surgical contexts. Prior to May 1973, the organization operated under the name Idant Corporation.
Quick stats
Shares outstanding5.8M
Computed float3.0M
Float / shares51.1%
Key info
SectorHealthcare
IndustryMedical - Instruments & Supplies
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0000027367
Websitehttps://www.daxor.com
AI Summary
AI-generated1/9
minorbullishproduct launch
Daxor to Showcase Next-Gen Blood Volume Analyzer and New Clinical Data at HFSA 2026
Daxor will showcase its FDA 510(k)-cleared next-generation Blood Volume Analyzer at the HFSA Annual Scientific Meeting in Phoenix, October 9-12, 2026, including a Device Day appearance and Booth #803 demonstrations.
The new platform operates 3x faster than the predecessor BVA-100, requires 50% less blood per test, and delivers >95% measurement accuracy.
Independent investigators will present two ePosters on BVA-guided volume management in advanced heart failure, LVAD, and total artificial heart patients -- a commercial-evidence push, not a new clinical readout.